ADL 08-0011,
156130-41-5,
(S)-2-Benzyl-3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanoic acid,
Alvimopan Metabolite,
ADL 08-0011,
UNII-3I1G16537O,
3I1G16537O,
(S)-2-benzyl-3-[(3R,4R)-4-(3-Hydroxyphenyl)-3,4-diMethylpiperidin-1-yl]propanoic acid,
ADL-08-0011,
ADL-08-0011, (+)-,
SCHEMBL3770460,
CTK8B9656,
DTXSID30433261,
KSBSLJKYJXTATP-WCAVRKLYSA-N,
ANW-62851,
ZINC13737816,
1-Piperidinepropanoic acid, 4-(3-hydroxyphenyl)-3,4-dimethyl-alpha-(phenylmethyl)-, (3R-(1(S*),3alpha,4alpha))-,
1-Piperidinepropanoic acid, 4-(3-hydroxyphenyl)-3,4-dimethyl-alpha-(phenylmethyl)-, (alphaS,3R,4R)-,
AJ-64349,
AX8233137,
TC-151596,
FT-0661432,
J-009277,
(|AS,3R,4R)-4-(3-Hydroxyphenyl)-3,4-dimethyl-|A-(phenylmethyl)-1-piperidinepropanoic Acid,
(s)-2-benzyl-3-[(3r,4r)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl] propionic acid,
[3R-[1(S*),3|A,4|A]]-4-(3-Hydroxyphenyl)-3,4-dimethyl-|A-(phenylmethyl)-1-piperidinepropanoic Acid,
Alvimopan Amide Hydrolyzed Metabolite,
CID9951118,
CS-O-03665,
2-benzyl-3-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidyl]propanoic Acid,